The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Post-transcriptional expression levels of many genes can be controlled by RNA interference, in which miRNAs, specific short RNA molecules, pair with mRNA regions and target them for repression. RNA interference is carried out by the RNA-induced silencing complex, which uses a miRNA guide to regulate complementary mRNAs through base pairing interactions and results in either degradaing the mRNA or blocking its translation.
The South Atlantic plant was built in 1987 in Charleston, SC. At 1,500,000 cubic feet (42,000 m3), this facility can blast freeze up to 320,000 lbs of meat and poultry a day. There are 16 truck platforms and the warehouse is accessible to all railroads that serve Charleston, SC (Norfolk Southern and CSX directly). This facility is certified for Russian meat and poultry shipments.
=== Suggested limits on consumption of solanine === Toxicity typically occurs when people ingest potatoes containing high levels of solanine. The average consumption of potatoes in the U.S. is estimated to be about 167 g of potatoes per day per person. There is variation in glycoalkaloid levels in different types of potatoes, but potato farmers aim to keep solanine levels below 0.2 mg/g. Signs of solanine poisoning have been linked to eating potatoes with solanine concentrations of between 0.1 and 0.4 mg per gram of potato. The average potato has 0.075 mg solanine/g potato, which is equal to about 0.18 mg/kg based on average daily potato consumption. Calculations have shown that 2 to 5 mg/kg of body weight is the likely toxic dose of glycoalkaloids like solanine in humans, with 3 to 6 mg/kg constituting the fatal dose. Other studies have shown that symptoms of toxicity were observed with consumption of even 1 mg/kg.
=== Cross-linking immunoprecipitation (CLIP) === CLIP analyzes protein interactions with RNA by combining UV cross-linking and immunoprecipitation. CLIP-based techniques are able to map RNA binding protein binding sites of interest on a genome-wide scale. There are many CLIP-based methods including:
Williams contributed to understanding of the distribution of the chemical elements in living organisms and in collaborationwith João J. R. Fraústo da Silva he wrote three books in this area, as well as a book with Rosalind Rickaby on geological aspects of life. Williams retired in 1991 and devoted much of his retirement to the writing of the books mentioned.
Sources: en.wikipedia.org
In a study by Belicka et al., six sediment cores from two shelf-basin transects in the Chukchi and Beaufort Seas of the Arctic Ocean were examined in order to compare the sources and preservation of organic carbon between the two differing depositional regimes. This study found an unexpected correlation between dinosterol and α-amyrin, which is found in terrestrial plants, in shelf and slope sediments, in particular the Beaufort Shelf, suggesting that dinoflagellates contribute significantly to phytoplankton abundance in areas of seasonal open water. Dinosterol was only observed above the permanent ice pack, suggesting that dinoflagellates are restricted to open waters, which in the Arctic occur near the shallow shelves. Consequently, dinosterol may be a potential indicator of the history of open water conditions.
== Medicine and biotechnology == Aminopeptidase has been studied for use in treating hypertension, inflammation, and some cancers. Aminopeptidase A (APA) is implicated in blood pressure regulation by converting angiotensin II to angiotensin III. APA inhibitors are being explored as potential antihypertensive agents, offering a novel approach to managing hypertension. Aminopeptidase N (APN) has been associated with the pathogenesis of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Inhibitors of APN have demonstrated anti-inflammatory effects in animal models, positioning them as potential therapeutic agents for these conditions. Several aminopeptidases, including APN, APA, and leucine aminopeptidase (LAP), are overexpressed in various cancers. Their involvement in tumor growth, invasion, and angiogenesis makes them attractive targets for cancer therapy. Aminopeptidase inhibitors have shown promise in preclinical studies as potential anticancer agents.
A third form can sometimes be encountered in which the spaces below yttrium in group 3 are left empty, such as the table appearing on the IUPAC web site, but this creates an inconsistency with quantum mechanics by making the f-block 15 elements wide (La–Lu and Ac–Lr) even though only 14 electrons can fit in an f-subshell. There is moreover some confusion in the literature on which elements are then implied to be in group 3. While the 2021 IUPAC report noted that 15-element-wide f-blocks are supported by some practitioners of a specialized branch of relativistic quantum mechanics focusing on the properties of superheavy elements, the project's opinion was that such interest-dependent concerns should not have any bearing on how the periodic table is presented to "the general chemical and scientific community". Other authors focusing on superheavy elements since clarified that the "15th entry of the f-block represents the first slot of the d-block which is left vacant to indicate the place of the f-block inserts", which would imply that this form still has lutetium and lawrencium (the 15th entries in question) as d-block elements in group 3. Indeed, when IUPAC publications expand the table to 32 columns, they make this clear and place lutetium and lawrencium under yttrium in group 3. Several arguments in favour of Sc-Y-La-Ac can be encountered in the literature, but they have been challenged as being logically inconsistent.
=== Disparities in care === The stigma of mental health is perceived differently due to historical and cultural context. Attitudes regarding treatments and seeking services are influenced by the impact of society's stigma associated with mental health. Many communities with different ethnic backgrounds, socioeconomic statuses, and cultural beliefs experience poor treatment and fewer easily accessible, quality-care resources.
To reduce the cost to the military of maintaining stockpiles of certain pharmaceuticals, the United States Department of Defense (DoD) and the Food and Drug Administration (FDA) operate a joint initiative known as the Shelf Life Protection Program (SLEP), which evaluates the long-term effectiveness of medications stockpiled by the DoD and other government agencies. Under the program, medications are tested for safety and stability for extended periods of time in controlled storage conditions. In many cases, medications tested were found to be effective for years past their printed expiry dates; a 2006 study by the Journal of Pharmaceutical Sciences found that two-thirds of 122 medications tested through SLEP remained effective for an average of at least four additional years. In 2016, the DoD reported that the program had helped save the department US$2.1 billion on replacing stockpiled medications. While testing and stability assessment found that 88% of the lots were effective at least one year after their expiration date, with an average extension of 66 months, the additional stability period was very variable. For antibiotics studied, the mean extension for ciprofloxacin was 55 months, and for amoxicillin 23 months.
Sources: en.wikipedia.org
In the TQMS, several ionization methods can be employed. Some of these include electrospray ionization, chemical ionization, electron ionization, atmospheric pressure chemical ionization, and matrix-assisted laser desorption ionization, all of which produce a continuous supply of ions. Both, the first mass analyzer and the collision cell are continuously exposed to ions from the source, in a time independent manner. It is once the ions move into the third mass analyzer that time dependence becomes a factor. The first quadrupole mass filter, Q1, is the primary m/z selector after the sample leaves the ionization source. Any ions with mass-to-charge ratios other than the one selected for will not be allowed to infiltrate Q1. The collision cell, denoted as "q", is located between Q1 and Q3, is where fragmentation of the sample occurs in the presence of an inert gas like Ar, He, or N2. A characteristic daughter ion is produced as a result of the collisions of the inert gas with the analyte. Upon exiting the collision cell, the fragmented ions then travel onto the second quadrupole mass filter, Q3, where m/z selection can occur again. Because the triple quadrupole is a scanning instrument, the type of detection system it employs must be capable of detecting ions one m/z at a time. One of the most common detectors, the electron multiplier, is often paired with the triple quadrupole. The electron multiplier allows for faster response time, increased sensitivity and higher gain. However, they have a limited lifetime due to overloading.
== Pipeline drugs == Lucitanib is a tyrosine kinase activity inhibitor, highly selective for VEGFR types 1-3, FGFR types 1-2 and PDGFR alpha/beta. Tumor types such as breast carcinoma show amplification of fibroblast growth factor related genes. Simultaneous inhibition of VEGF and FGF receptors in FGFR1 dependent tumors could be therapeutically advantageous. Lucitanib has been shown to have promising efficacy, a manageable side-effect profile and clinical benefits in both FGF-aberrant and angiogenesis-sensitive populations leading to a phase II program being planned. Motesanib is a small-molecule multikinase inhibitor highly selective for VEGFR 1-3, PDGFR and KIT. The drug has shown anti-tumor activity as a monotherapy in advanced solid tumors. Vatalanib is an antiangiogenic VEGFR inhibiting molecule which is being researched as a potential treatment of solid tumors. Vatalanib inhibits VEGFR 1-4 although it has greater potency as an inhibitor of VEGFR 1-2. At concentrations under 10 μM, Vatalanib does not have cytotoxic or antiproliferative effects on cells that do not express VEGF. Specific inhibition of tumor-induced angiogenesis like the inhibition by Vatalanib can both prevent ongoing growth of tumors and the metastatic potential. Cediranib is a multi VEGFR 1-3 inhibitor being tested as a maintenance treatment for patients with platinum sensitive relapsed ovarian cancer. Cediranib stops blood flow to the site of the tumour and thereby inhibits its growth.
-values are taken from AME2020, while the electron binding energies are taken from NIST. See (Ran & Wang, 2026) for more details. Please note that the ionization energies for highly-ionized atoms are theoretical.
=== United Kingdom === GDK's first store in the United Kingdom, was opened on 6 July 2015, on Bull Street in Birmingham, England. In May 2019, it was estimated that the chain served £1 million worth of kebabs in its restaurants in the UK every week. GDK also announced their plan to open a new restaurant every two weeks for the remainder of 2019 as part of a "relentless UK growth" plan. In September 2019, GDK's Fulham Broadway site was classed as London's number one place to eat on Tripadvisor. In October 2020, it had 47 restaurants, with hopes by the company to open a further 12 by the end of 2020. In December 2020, its Peterborough new restaurant marked its 50th UK restaurant. In February 2021, the chain announced its plan to open 47 restaurants by the end of 2021 in the UK. It opened 39 new restaurants in the UK in 2021, adding to their pre-existing 52 restaurants at the start of 2021. In February 2022, the company announced its plan to open 78 more restaurants in the UK in 2022, bringing their total to 170 restaurants in the UK. Adding 2,900 workers to their 3,500 workforce at the time in the UK. The chain opened their 100th UK restaurant at their Covent Garden, London site on 10 May 2022. In June 2022, Atul Pathak, former owner of the largest McDonald's franchise in the UK of 43 restaurants, announced a partnership with GDK, with 30 planned sites to be set up in the UK as part of the deal. In January 2025, German Doner Kebab (GDK) opened its first London train station location at Victoria Station, marking its 144th UK outlet and 55th in the capital.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.